Amplify Weight Loss Drug & Treatment ETF (THNR)

Assets	$3.16M
Expense Ratio	0.59%
PE Ratio	25.49
Shares Out	150,000
Dividend (ttm)	$0.22
Dividend Yield	1.05%
Ex-Dividend Date	Dec 30, 2024
Payout Ratio	26.64%
1-Year Return	n/a

Volume	n/a
Open	n/a
Previous Close	20.66
Day's Range	n/a
52-Week Low	18.56
52-Week High	28.19
Beta	n/a
Holdings	27
Inception Date	May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: NYSEARCA
• Ticker Symbol: THNR
• ETF Provider: Amplify Investments
• Index Tracked: VettaFi Weight Loss Drug Index

Top 10 Holdings

71.06% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	16.81%
Novo Nordisk A/S	NVO	12.93%
Chugai Pharmaceutical Co., Ltd.	4519	6.78%
Innovent Biologics, Inc.	1801	6.05%
West Pharmaceutical Services, Inc.	WST	4.92%
Roche Holding AG	ROG	4.84%
AstraZeneca PLC	AZN	4.75%
Amgen Inc.	AMGN	4.67%
Teva Pharmaceutical Industries Limited	TEVA	4.67%
Pfizer Inc.	PFE	4.65%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 30, 2024	$0.2199	Dec 31, 2024